Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans NICE has to review recent research on the (a) use of and (b) eligibility for Spinraza for treatment of type three spinal muscular atrophy.

The National Institute for Health and Care Excellence (NICE) has committed to reviewing new evidence that becomes available for non-ambulant spinal muscular atrophy type 3 patients during the five-year course of the existing managed access agreement (MAA). This review will assess whether any new evidence has become available to support a change in the MAA treatment eligibility criteria.

NICE expects to commence the review later this year.